### 广州7月19日电（记者 蔡敏婕）
随着现代医学的不断进步，面对恶性程度极高的脑胶质瘤，专家们正积极探索更加高效、个性化的治疗策略。近日，中山大学肿瘤防治中心神经外科主任医师杨群英教授在一次学术研讨会上表示，未来通过联合应用多种治疗手段，有望实现对脑胶质瘤的精准治疗，显著提升患者的生存质量和治疗效果。
脑胶质瘤，尤其是胶质母细胞瘤，作为星形细胞肿瘤中恶性程度最高的类型，长期以来一直是医学界的一大挑战。传统的治疗方法包括手术切除、放疗和化疗，但这些方法在应对高度异质性和快速进展的胶质瘤时，往往难以取得满意的效果。近年来，靶向治疗和免疫治疗的兴起，为这一领域带来了新的希望。
靶向治疗通过针对肿瘤细胞特有的分子标记或信号通路，精准打击肿瘤细胞，减少对正常细胞的伤害，从而提高治疗的针对性和安全性。免疫治疗则利用人体自身的免疫系统，激发或增强免疫细胞对肿瘤的识别和攻击能力，达到抑制或消除肿瘤的效果。这两种治疗方法的结合，不仅能够提升治疗效果，还可能克服单一治疗手段的局限性，为患者提供更加全面、个性化的治疗方案。
杨群英教授强调，未来，通过精确的肿瘤基因分型、精准的治疗策略选择、以及个体化免疫治疗方案的定制，结合手术、放疗、化疗、靶向治疗和免疫治疗等多种手段的联合应用，有望实现对脑胶质瘤的高效治疗，为患者带来生存期的显著延长和生活质量的提升。
这一研究成果不仅对脑胶质瘤的临床治疗具有重要指导意义，也为其他恶性肿瘤的治疗提供了新的思路和方向。未来，随着相关研究的深入和临床实践的积累，多手段联合治疗有望成为脑胶质瘤治疗的新常态，为患者带来更多的生存希望和生活质量的改善。
### 结语
面对脑胶质瘤这一严峻挑战，多手段联合治疗的探索和实践正逐渐成为可能。随着科技的发展和医学研究的深入，我们有理由相信，通过整合多种治疗手段，未来将能为脑胶质瘤患者提供更加高效、个性化的治疗方案，为他们带来新的希望和改善生活质量的机会。
英语如下：
### New Hope for Brain Glioma Treatment: Multi-Approach Collaboration Promises High-Efficiency Breakthroughs
With the continuous advancement of modern medicine, experts are actively exploring more efficient and personalized treatment strategies for the highly malignant brain glioma. Professor Yang Qunying, the head of neurosurgery at the Department of Oncology at Sun Yat-sen University Cancer Center, highlighted in a recent academic forum that the use of multiple treatment approaches in combination could lead to precise treatment of brain glioma, significantly enhancing the survival quality and treatment outcomes for patients.
Brain glioma, particularly glioblastoma, as the most malignant type of astrocytoma, has long posed a significant challenge to the medical community. Traditional treatments, including surgical removal, radiation therapy, and chemotherapy, often fall short in addressing the high heterogeneity and rapid progression of gliomas. In recent years, the emergence of targeted therapy and immunotherapy has brought new hope to this field.
Targeted therapy focuses on striking cancer cells with specific molecular markers or signaling pathways, minimizing damage to normal cells and enhancing the treatment’s specificity and safety. Immunotherapy, on the other hand, leverages the body’s own immune system to stimulate or enhance the ability of immune cells to recognize and attack tumors, effectively inhibiting or eliminating tumors. The combination of these two methods not only enhances the treatment effect but also overcomes the limitations of single-treatment approaches, offering patients more comprehensive and personalized treatment options.
Professor Yang Qunying emphasizes that with the precision of tumor gene typing, the selection of precise treatment strategies, and the customization of individualized immunotherapy schemes, combined with the use of multiple approaches such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, it is hoped that a high-efficiency treatment of brain glioma can be achieved. This could lead to a significant extension of survival time and improvement in the quality of life for patients.
This research not only holds significant implications for the clinical treatment of brain glioma but also opens up new avenues for the treatment of other malignant tumors. As related studies deepen and clinical practice accumulates, the integration of multiple treatment approaches is expected to become the norm in the treatment of brain glioma, offering patients more opportunities for survival and improvement in the quality of life.
### Conclusion
Faced with the serious challenge of brain glioma, the exploration and practice of multi-approach treatments are becoming increasingly feasible. With the development of technology and the advancement of medical research, it is reasonable to believe that through the integration of various treatment approaches, we can provide brain glioma patients with more efficient and personalized treatment plans, bringing them new hopes and opportunities to improve the quality of life.
【来源】http://www.chinanews.com/life/2024/07-19/10253977.shtml
Views: 1